Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMX0035 (Relyvrio) OLE in ALS
NCT05619783Phase 3Completed
- Sponsor
- Amylyx Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of sodium phenylbutyrate in amyotrophic lateral sclerosis (ALS), sponsored by Amylyx Pharmaceuticals. Started Dec 2022; status: completed.
02
Drugs
sodium phenylbutyrate
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05619783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05619783.